KR100700319B1 - 반감기가 단축된 테트라졸-함유 라파마이신 유사체를포함하는 약제학적 조성물 - Google Patents
반감기가 단축된 테트라졸-함유 라파마이신 유사체를포함하는 약제학적 조성물 Download PDFInfo
- Publication number
- KR100700319B1 KR100700319B1 KR1020067011149A KR20067011149A KR100700319B1 KR 100700319 B1 KR100700319 B1 KR 100700319B1 KR 1020067011149 A KR1020067011149 A KR 1020067011149A KR 20067011149 A KR20067011149 A KR 20067011149A KR 100700319 B1 KR100700319 B1 KR 100700319B1
- Authority
- KR
- South Korea
- Prior art keywords
- diseases
- compound
- compounds
- formula
- rapamycin
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
실시예 | 사람 MLR IC50 ± S.E.M.(nM) |
라파마이신 | 0.91±0.36 |
실시예 1의 화합물 | 1.70±0.48 |
실시예 2의 화합물 | 0.66±0.19 |
Claims (4)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93814497A | 1997-09-26 | 1997-09-26 | |
US08/938,144 | 1997-09-26 | ||
KR1020007003197A KR100803639B1 (ko) | 1997-09-26 | 1998-09-24 | 반감기가 단축된 테트라졸-함유 라파마이신 유사체 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020007003197A Division KR100803639B1 (ko) | 1997-09-26 | 1998-09-24 | 반감기가 단축된 테트라졸-함유 라파마이신 유사체 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060071092A KR20060071092A (ko) | 2006-06-26 |
KR100700319B1 true KR100700319B1 (ko) | 2007-03-29 |
Family
ID=25470968
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020007003197A KR100803639B1 (ko) | 1997-09-26 | 1998-09-24 | 반감기가 단축된 테트라졸-함유 라파마이신 유사체 |
KR1020077015322A KR100833812B1 (ko) | 1997-09-26 | 1998-09-24 | 반감기가 단축된 테트라졸-함유 라파마이신 유사체의프로드럭 |
KR1020067011149A KR100700319B1 (ko) | 1997-09-26 | 1998-09-24 | 반감기가 단축된 테트라졸-함유 라파마이신 유사체를포함하는 약제학적 조성물 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020007003197A KR100803639B1 (ko) | 1997-09-26 | 1998-09-24 | 반감기가 단축된 테트라졸-함유 라파마이신 유사체 |
KR1020077015322A KR100833812B1 (ko) | 1997-09-26 | 1998-09-24 | 반감기가 단축된 테트라졸-함유 라파마이신 유사체의프로드럭 |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1015459B9 (ko) |
JP (1) | JP3790424B2 (ko) |
KR (3) | KR100803639B1 (ko) |
CN (1) | CN1161360C (ko) |
AR (1) | AR015940A1 (ko) |
AT (1) | ATE297398T1 (ko) |
AU (1) | AU745576B2 (ko) |
BG (1) | BG64955B1 (ko) |
BR (1) | BR9812305A (ko) |
CA (1) | CA2303934C (ko) |
CO (1) | CO5070656A1 (ko) |
CZ (1) | CZ299365B6 (ko) |
DE (1) | DE69830502T2 (ko) |
DK (1) | DK1015459T3 (ko) |
ES (1) | ES2244087T3 (ko) |
HK (1) | HK1030771A1 (ko) |
HU (1) | HU228368B1 (ko) |
IL (2) | IL134607A0 (ko) |
NO (1) | NO325813B1 (ko) |
NZ (2) | NZ502896A (ko) |
PL (1) | PL191212B1 (ko) |
PT (1) | PT1015459E (ko) |
SI (1) | SI1015459T1 (ko) |
SK (1) | SK285408B6 (ko) |
TR (1) | TR200000778T2 (ko) |
TW (1) | TW557297B (ko) |
WO (1) | WO1999015530A1 (ko) |
ZA (1) | ZA988750B (ko) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
US7399480B2 (en) | 1997-09-26 | 2008-07-15 | Abbott Laboratories | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices |
US7357942B2 (en) * | 1997-09-26 | 2008-04-15 | Abbott Laboratories | Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens |
US7960405B2 (en) | 1998-09-24 | 2011-06-14 | Abbott Laboratories | Compounds and methods for treatment and prevention of diseases |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
EP1482975B1 (en) * | 2002-01-29 | 2006-12-13 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Prevention of tissue adhesion |
US20030176455A1 (en) * | 2002-03-13 | 2003-09-18 | Wyeth | Method of inhibiting cell death |
EP1944026B1 (en) | 2002-05-16 | 2013-06-26 | Novartis AG | Use of EDG receptor binding agents in cancer |
WO2003099192A2 (en) | 2002-05-27 | 2003-12-04 | Novartis Ag | Bis-aromatic alkanols |
AU2003218077B2 (en) * | 2002-09-06 | 2009-10-08 | Abbott Laboratories | Medical device having hydration inhibitor |
EP2251007A3 (en) | 2002-09-24 | 2011-03-23 | Novartis AG | Sphingosine-1-phosphate (S1P) receptor agonists for use in the treatment of demyelinating diseases |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
AR044402A1 (es) | 2003-05-19 | 2005-09-14 | Irm Llc | Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. |
EP1768662A2 (en) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
CN101048152A (zh) | 2004-10-28 | 2007-10-03 | 惠氏公司 | mTOR抑制剂在治疗子宫平滑肌瘤中的应用 |
GB0504544D0 (en) | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
US20090062909A1 (en) | 2005-07-15 | 2009-03-05 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
JP5756588B2 (ja) | 2005-07-15 | 2015-07-29 | ミセル テクノロジーズ、インコーポレイテッド | 制御されたモルホロジーの薬剤粉末を含むポリマーコーティング |
PT2298815E (pt) | 2005-07-25 | 2015-07-16 | Emergent Product Dev Seattle | Moléculas de ligaçao especificas para cd37 e especificas para cd20 |
BRPI0617057A2 (pt) | 2005-08-30 | 2011-07-12 | Univ Miami | anticorpo isolado, toxina especìfica para receptor de fator de necrose tumoral 25 (tnfr25), método para ativar o receptor de fator de necrose tumoral 25 (tnfr25), método para inibir a sinalização do receptor de fator de necrose tumoral 25 (tnfr25) numa célula, vacina antitumoral, método para imunizar um paciente contra tumor, método para tratar cáncer num paciente, método para tratar e/ou prevenir inflamação intestinal, composição terapêutica para a facilitação de um transplante de órgão, método para transplantar um tecido de um doador para um hospedeiro, método para inibir a expressão clonal de uma população de células t cd8 cognatas, método para tratar e/ou prevenir inflamação pulmonar, antagonista de tnfr25 isolado, composição e vetor de expressão |
AR057854A1 (es) | 2005-11-04 | 2007-12-19 | Wyeth Corp | Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida |
US7700614B2 (en) * | 2005-12-14 | 2010-04-20 | Abbott Laboratories | One pot synthesis of tetrazole derivatives of rapamycin |
PL2019657T3 (pl) | 2006-04-26 | 2015-10-30 | Micell Technologies Inc | Powłoki zawierające wiele leków |
US7820812B2 (en) | 2006-07-25 | 2010-10-26 | Abbott Laboratories | Methods of manufacturing crystalline forms of rapamycin analogs |
US7812032B2 (en) * | 2006-07-25 | 2010-10-12 | Abbott Laboratories | Crystalline forms of rapamycin analogs |
EP2051984A1 (en) * | 2006-07-25 | 2009-04-29 | Abbott Laboratories | Crystalline forms of rapamycin analogs |
EP2111184B1 (en) | 2007-01-08 | 2018-07-25 | Micell Technologies, Inc. | Stents having biodegradable layers |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
TW200901989A (en) | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
CA2719134C (en) | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
CA2719924C (en) | 2008-04-11 | 2017-10-03 | Philip Tan | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
MX2010011485A (es) | 2008-04-17 | 2011-03-01 | Micell Technologies Inc | Stents que contienen capas bioadsorbibles. |
CN102076335A (zh) | 2008-06-20 | 2011-05-25 | 诺瓦提斯公司 | 用于治疗多发性硬化的儿科组合物 |
WO2011009096A1 (en) | 2009-07-16 | 2011-01-20 | Micell Technologies, Inc. | Drug delivery medical device |
AU2009270849B2 (en) | 2008-07-17 | 2013-11-21 | Micell Technologies, Inc. | Drug delivery medical device |
CN102256942B (zh) | 2008-12-18 | 2013-07-24 | 诺瓦提斯公司 | 1-(4-{1-[(e)-4-环己基-3-三氟甲基-苄氧基亚氨基]-乙基}-2-乙基-苄基)-氮杂环丁烷-3-甲酸的多晶型物 |
EP2379499B1 (en) | 2008-12-18 | 2014-04-09 | Novartis AG | Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid |
KR20110096584A (ko) | 2008-12-18 | 2011-08-30 | 노파르티스 아게 | 1-[4-[1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸]-2-에틸-벤질]-아제티딘-3-카르복실산의 헤미푸마레이트 염 |
JP2012522589A (ja) | 2009-04-01 | 2012-09-27 | ミシェル テクノロジーズ,インコーポレイテッド | 被覆ステント |
WO2010121187A2 (en) | 2009-04-17 | 2010-10-21 | Micell Techologies, Inc. | Stents having controlled elution |
ES2586837T3 (es) | 2009-08-03 | 2016-10-19 | University Of Miami | Método para la expansión in vivo de linfocitos T reguladores |
EA201290255A1 (ru) | 2009-10-30 | 2013-04-30 | Ариад Фармасьютикалз, Инк. | Способы и композиции для лечения рака |
US11369498B2 (en) | 2010-02-02 | 2022-06-28 | MT Acquisition Holdings LLC | Stent and stent delivery system with improved deliverability |
WO2011100401A1 (en) | 2010-02-11 | 2011-08-18 | Bristol-Myers Squibb Company | Macrocycles as factor xia inhibitors |
CA2797110C (en) | 2010-04-22 | 2020-07-21 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
RU2585489C2 (ru) | 2010-04-27 | 2016-05-27 | Рош Гликарт Аг | КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR |
CN102234288B (zh) * | 2010-05-06 | 2014-07-02 | 上海医药工业研究院 | 唑他莫司的制备方法 |
CA2805631C (en) | 2010-07-16 | 2018-07-31 | Micell Technologies, Inc. | Drug delivery medical device |
CN103732226B (zh) | 2011-02-18 | 2016-01-06 | 诺瓦提斯药物公司 | mTOR/JAK抑制剂组合疗法 |
JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用 |
US10117972B2 (en) | 2011-07-15 | 2018-11-06 | Micell Technologies, Inc. | Drug delivery medical device |
HUE034857T2 (en) | 2011-10-14 | 2018-03-28 | Bristol Myers Squibb Co | Substituted tetrahydroisoquinoline compounds are inhibitors of factor XIA |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
EP2906551B1 (en) | 2012-10-12 | 2018-02-28 | Bristol-Myers Squibb Company | Crystalline forms of a factor xia inhibitor |
EP2906541B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
WO2014059202A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
CA2863243A1 (en) * | 2012-11-30 | 2014-06-05 | Hangzhou Zylox Pharma Co., Ltd. | Rafamycin analogs and methods for making same |
WO2014110258A1 (en) | 2013-01-09 | 2014-07-17 | Podack Eckhard R | Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein |
CN105307597A (zh) | 2013-03-12 | 2016-02-03 | 脉胜医疗技术公司 | 可生物吸收的生物医学植入物 |
JP6479763B2 (ja) | 2013-03-25 | 2019-03-06 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 第xia因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン |
WO2014186532A1 (en) | 2013-05-15 | 2014-11-20 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
AU2014348657A1 (en) | 2013-11-13 | 2016-05-19 | Novartis Ag | mTOR inhibitors for enhancing the immune response |
US10640569B2 (en) | 2013-12-19 | 2020-05-05 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
CN103739616B (zh) * | 2013-12-27 | 2015-12-30 | 福建省微生物研究所 | 含噻唑基雷帕霉素类衍生物及其应用 |
US10428331B2 (en) | 2014-01-16 | 2019-10-01 | Musc Foundation For Research Development | Targeted nanocarriers for the administration of immunosuppressive agents |
NO2760821T3 (ko) | 2014-01-31 | 2018-03-10 | ||
CN106132962B (zh) | 2014-01-31 | 2018-09-07 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的具有芳族p2’基团的大环化合物 |
ES2939760T3 (es) | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
US20170081411A1 (en) | 2014-03-15 | 2017-03-23 | Novartis Ag | Regulatable chimeric antigen receptor |
CA2943609A1 (en) | 2014-03-27 | 2015-10-01 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
IL280215B (en) | 2014-04-07 | 2022-07-01 | Novartis Ag | Cancer treatment using a chimeric receptor antigen (car) against cd19 |
JP2017518307A (ja) | 2014-06-02 | 2017-07-06 | チルドレンズ メディカル センター コーポレーション | 免疫調節のための方法および組成物 |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
JP6831777B2 (ja) | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Cd33キメラ抗原受容体を使用する癌の処置 |
JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ |
EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
US10851149B2 (en) | 2014-08-14 | 2020-12-01 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using GFR α-4 chimeric antigen receptor |
CN107108744B (zh) | 2014-08-19 | 2020-09-25 | 诺华股份有限公司 | 抗cd123嵌合抗原受体(car)用于癌症治疗 |
ES2714283T3 (es) | 2014-09-04 | 2019-05-28 | Bristol Myers Squibb Co | Macrociclos de diamida que son inhibidores de FXIa |
CA2961636A1 (en) | 2014-09-17 | 2016-03-24 | Boris ENGELS | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
CN106973568B (zh) | 2014-10-08 | 2021-07-23 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
ES2948133T3 (es) | 2015-04-17 | 2023-08-31 | Novartis Ag | Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
CN107847491A (zh) | 2015-05-20 | 2018-03-27 | 诺华公司 | 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合 |
US11357851B2 (en) | 2015-11-11 | 2022-06-14 | Novartis Ag | Uses of myostatin antagonists, combinations containing them and uses thereof |
CN116769050A (zh) | 2016-07-20 | 2023-09-19 | 犹他大学研究基金会 | Cd229 car t细胞及其使用方法 |
TW202340473A (zh) | 2016-10-07 | 2023-10-16 | 瑞士商諾華公司 | 利用嵌合抗原受體之癌症治療 |
CA3044355A1 (en) | 2016-11-23 | 2018-05-31 | Novartis Ag | Methods of enhancing immune response with everolimus, dactolisib or both |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
CA3107352A1 (en) | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
CA3107349A1 (en) | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
JP2022526671A (ja) | 2019-04-11 | 2022-05-25 | エンクリアー セラピーズ, インク. | 脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム |
EP4240356A1 (en) | 2020-11-03 | 2023-09-13 | RDiscovery, LLC | Therapies for treatment of cancer and phagocytosis-deficiency related diseases |
EP4370160A1 (en) | 2021-07-15 | 2024-05-22 | President And Fellows Of Harvard College | Compositions and methods relating to cells with adhered particles |
CN116082362B (zh) * | 2023-01-04 | 2024-05-10 | 山东大学 | 一种可用于合成靶向抗肿瘤药物的氨甲酰美登醇及其合成方法与应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995014023A1 (en) * | 1993-11-19 | 1995-05-26 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
AU4246197A (en) * | 1996-09-09 | 1998-03-26 | American Home Products Corporation | Rapamycin derivatives with unnatural stereochemistries |
CN1235608A (zh) * | 1996-09-09 | 1999-11-17 | 美国家用产品公司 | 烷基化的雷帕霉素衍生物 |
-
1998
- 1998-09-08 TW TW087114877A patent/TW557297B/zh not_active IP Right Cessation
- 1998-09-23 ZA ZA988750A patent/ZA988750B/xx unknown
- 1998-09-24 DK DK98949512T patent/DK1015459T3/da active
- 1998-09-24 PL PL339455A patent/PL191212B1/pl unknown
- 1998-09-24 KR KR1020007003197A patent/KR100803639B1/ko not_active IP Right Cessation
- 1998-09-24 CZ CZ20001014A patent/CZ299365B6/cs not_active IP Right Cessation
- 1998-09-24 AT AT98949512T patent/ATE297398T1/de active
- 1998-09-24 TR TR2000/00778T patent/TR200000778T2/xx unknown
- 1998-09-24 ES ES98949512T patent/ES2244087T3/es not_active Expired - Lifetime
- 1998-09-24 DE DE69830502T patent/DE69830502T2/de not_active Expired - Lifetime
- 1998-09-24 BR BR9812305-0A patent/BR9812305A/pt active Search and Examination
- 1998-09-24 CN CNB988094223A patent/CN1161360C/zh not_active Expired - Lifetime
- 1998-09-24 IL IL13460798A patent/IL134607A0/xx active IP Right Grant
- 1998-09-24 HU HU0004556A patent/HU228368B1/hu unknown
- 1998-09-24 SI SI9830781T patent/SI1015459T1/xx unknown
- 1998-09-24 PT PT98949512T patent/PT1015459E/pt unknown
- 1998-09-24 WO PCT/US1998/020111 patent/WO1999015530A1/en not_active Application Discontinuation
- 1998-09-24 SK SK417-2000A patent/SK285408B6/sk not_active IP Right Cessation
- 1998-09-24 KR KR1020077015322A patent/KR100833812B1/ko not_active IP Right Cessation
- 1998-09-24 KR KR1020067011149A patent/KR100700319B1/ko not_active IP Right Cessation
- 1998-09-24 AU AU95819/98A patent/AU745576B2/en not_active Expired
- 1998-09-24 NZ NZ502896A patent/NZ502896A/en not_active IP Right Cessation
- 1998-09-24 NZ NZ514778A patent/NZ514778A/en not_active IP Right Cessation
- 1998-09-24 EP EP98949512A patent/EP1015459B9/en not_active Expired - Lifetime
- 1998-09-24 JP JP2000512835A patent/JP3790424B2/ja not_active Expired - Lifetime
- 1998-09-24 CO CO98055672A patent/CO5070656A1/es unknown
- 1998-09-24 CA CA2303934A patent/CA2303934C/en not_active Expired - Lifetime
- 1998-09-25 AR ARP980104798A patent/AR015940A1/es active IP Right Grant
-
2000
- 2000-02-17 IL IL134607A patent/IL134607A/en not_active IP Right Cessation
- 2000-03-20 NO NO20001438A patent/NO325813B1/no not_active IP Right Cessation
- 2000-04-07 BG BG104316A patent/BG64955B1/bg unknown
-
2001
- 2001-01-05 HK HK01100137A patent/HK1030771A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100700319B1 (ko) | 반감기가 단축된 테트라졸-함유 라파마이신 유사체를포함하는 약제학적 조성물 | |
US6015815A (en) | Tetrazole-containing rapamycin analogs with shortened half-lives | |
EP1832592A2 (en) | 15-C Isomers of rapamycin and of 42-EPI rapamycin, preparation and use thereof | |
US7678901B2 (en) | Rapamycin analogs containing an antioxidant moiety | |
EP1829881A1 (en) | Combination of rapamycin and its tetrazole isomers and epimers, methods of making and using the same | |
EP1826211A1 (en) | Isomers and 42-Epimers of rapamycin alkyl ether analogs, methods of making and using the same | |
EP1826212A1 (en) | Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same | |
US20070225313A1 (en) | Epimers and isomers of tetrazole containing rapamycin analogs, methods of making and using the same | |
MXPA00002976A (en) | Tetrazole-containing rapamycin analogs with shortened half-lives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
J202 | Request for trial for correction [limitation] | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CORRECTION REQUESTED 20090518 Effective date: 20100920 |
|
FPAY | Annual fee payment |
Payment date: 20130227 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140227 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150227 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20151230 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20161229 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20171228 Year of fee payment: 12 |
|
EXPY | Expiration of term |